Mibavademab
- Generic Name
- Mibavademab
- Drug Type
- Biotech
- CAS Number
- 2305770-44-7
- Unique Ingredient Identifier
- PHL2UDY3AB
- Background
Mibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy).
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT06548100
- Locations
- ๐บ๐ธ
National Institutes of Health, Bethesda, Maryland, United States
๐บ๐ธUniversity of Michigan, Ann Arbor, Michigan, United States
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT06373146
- Locations
- ๐บ๐ธ
Velocity Clinical Research, Gardena, Gardena, California, United States
๐บ๐ธIrvine Clinical Research, Irvine, California, United States
๐บ๐ธVelocity Clinical Research, Westlake, Los Angeles, California, United States
A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
- Conditions
- Familial Partial LipodystrophyMetabolic Abnormalities
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT05088460
- Locations
- ๐บ๐ธ
National Institute of Health, Bethesda, Maryland, United States
๐บ๐ธUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธExcel Medical Clinical Trials - A Flourish Research Site, Boca Raton, Florida, United States
Expanded Access to REGN4461 for Patients With Lipodystrophy or Monogenic Obesity With Complications of Leptin Deficiency or Deficient Leptin Signaling
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT04710056
A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT03530514
- Locations
- ๐ง๐ช
Regeneron Investigational Site, Antwerp, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.